CARB-X receives $50m from UK & Gates; Session at BIO on antibiotic reimbursement; PLOS opens an AMR Channel; CDD-sponsored SAR webinar

Dear All: There has been tremendously exciting activity in parallel with this week’s World Health Assembly! Here’s the list…

  • CARB-X has announced this week that the Bill & Melinda Gates Foundation and the UK government will contribute $25 million and £20 million ($26.9 million), respectively, over the next 3 years. With this new inflow of $50m in committed funds, CARB-X has raised more than $500 million. And the money is being applied at a furious pace: from its launch 21 months ago on 28 July 2016, CARB-X has funded 36 companies!! Showing that the projects are moving swiftly and the portfolio is being actively managed, 33 are still being funded and 3 have reached a project endpoint.
  • Antibiotic economics at BIO: The anti-infective track at the BIO meeting shows sessions that cover bacteria, fungi, and viruses. Note in particular these two:
    • The session at 11a on 6 June entitled “The value of addressing AMR” appears especially relevant to the entire community as its speakers include Colm Leonard of NICE and Mark Sculpher of the Economic Evaluation Policy Research Unit (EEPRU) at the University of York. Dr. Leonard gave an excellent talk assessing the value of antibiotics at the 6-8 Sep 2017 ASM-ESCMID developer’s conference and I would expect Dr. Sculpher to present results from the U of York EEPRU’s work on de-linking antibiotic reimbursement from usage.
    • The AMR Industry Alliance is sponsoring a session entitled “Forging antimicrobial R&D pacts” from 4-5p on 4 June that looks like a good panel discussion on challenges in the AMR space and ways to use partnership(s) to make progress.
  • PLOS announced that it has collaborated with GARDP to launch an AMR channel. Described as a global forum for AMR research, the press release says that the channel will provide research, commentaries, blogs, news, and discussions that span science, research and development, public health, and policy.
  • CDD (Collaborative Drug Discovery) will host a webinar on at 11a EST on 26 June on “SAR data in Drug Discovery”. Andrew Leach (ChEMBL) and Evan Bolton (PubChem) will discuss drug discovery informatics and ways to use the freely available PubChem and ChEMBL SAR data. This webinar is not specifically focused on AMR but rather looks like a good broad tour of tools that make SAR information more accessible.

All best wishes, –jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Expert-in-Residence, Wellcome Trust. Follow me on Twitter: @JohnRex_NewAbx. See past newsletters and subscribe for the future: https://13.43.35.2/blog/

Upcoming meetings of interest to the AMR community:

Scroll to Top